Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the third quarter ended September 30, 2008.

"We continue to make rapid progress in both of our hepatitis C development programs," said Steve Worland Ph.D., President and CEO of Anadys. "We completed our first clinical study of ANA598 in healthy volunteers and have now completed the healthy volunteer portion of our ongoing ANA773 study. For both programs, we are very encouraged by the data and look forward to initiating patient dosing this quarter."

Financial Results

As of September 30, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $34.4 million.

During the third quarter of 2008 the Company had no revenue, compared to $21.5 million for the same quarter of 2007. The revenue in the third quarter of 2007 was primarily derived from the recognition of previously deferred revenue associated with an upfront payment and a milestone payment under a prior collaboration.

Research and development expenses were $7.6 million for the third quarter of 2008 and 2007. During the third quarter of 2008, cost savings derived from Anadys' completed strategic restructuring and associated termination of prior development programs were offset by a significant increase in ANA598 development costs.

General and administrative expenses were $2.1 million for the third quarter of 2008, compared to $2.4 million for the third quarter of 2007. The $0.3 million decrease primarily resulted from cost savi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... ... manufacturing of surgical instruments in Orthopedics, announced today the acquisition of Turner ... world's largest provider of surgical instruments to the Spine Industry. The acquisition of ...
(Date:7/1/2015)... N.C. and PARIS ... firm AgBiome, and Genective, key developer of biotech ... the discovery of new generations of insect control ... insect control to counter the realities of advancing ... Genective, aligning AgBiome,s unique insect control technology with ...
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical ... segments, including the molecular diagnostics industry. BCC Research reveals in its new report that ... lower test costs, and a growing need for better diagnostics as part of a ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus ... the development of groundbreaking drugs to treat neurodegenerative ... today that Robert G. Miller , M.D., Director ... Sutter Health,s California Pacific Medical Center in San Francisco, ... Association for $1.5 million to help fund a ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
... Sweden has shown that biosynthetic corneas can help regenerate and ... results, from an early phase clinical trial with 10 patients, ... Science Translational Medicine . "This study is important because ... cornea can integrate with the human eye and stimulate regeneration," ...
... Enterprise Institute (Mtech) Bioprocess Scale-Up Facility (BSF) will double ... equipment, and create a pilot plant for biofuels in College ... from the Maryland Biotechnology Center . "The ... make sure the BSF,s capabilities are available to the growing ...
... bioserie is first to market with a line ... device owners the protection they demand while using only ... use of the latest in bioplastics technology offers considerably ... of environmental toxic pollution once the cover is discarded. ...
Cached Biology Technology:Seeing the world with new eyes: Biosynthetic corneas restore vision in humans 2Mtech Bioprocess Scale-Up Facility to Double in Staff and Size, Expand to Shady Grove, Create Pilot Plant for Biofuels in College Park 2Mtech Bioprocess Scale-Up Facility to Double in Staff and Size, Expand to Shady Grove, Create Pilot Plant for Biofuels in College Park 3bioserie Introduces the World's First 'Made of Plants' iPhone 4 Cover 2
(Date:6/25/2015)... SALT LAKE CITY , June 25, 2015 /PRNewswire/ ... the first steps toward a healthier, happier life. That,s ... app is designed to do. The cutting-edge, portable health ... and offers real-life solutions to help improve your lifestyle ... Sellers Association awards dinner and gala Wednesday night, USANA,s ...
(Date:6/24/2015)... Research and Markets( ... "Huawei Ascend Mate 7 Fingerprint Sensor - ... Huawei,s technological choice for the fingerprint ... Apple,s and Samsung,s one. The Ascend Mate 7 ... Cards, a main actor in capacitive sensing human ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... initial signs of fetal alcohol syndrome are slight but classic: facial ... openings and a short nose. Researchers want to know if ... it takes during what point in development to cause these and ... few glasses of wine over an hour in the first few ...
... -- Dr. Dilhan M. Kalyon, Professor of Chemical ... Institute at Stevens Institute of Technology, has won ... (in Memory of John C. Moricoli).Kalyon received his ... his M. Eng. and Ph.D. in Chemical Engineering/Polymers ...
... knows that there is more than one way to grow a ... a product claims it kills "99 percent" of bacteria, it really ... of bacteria that form on most wet surfaces. They range from ... the sludge that clogs pipes. Most biofilms are harmless, ...
Cached Biology News:Alcohol consumption can cause too much cell death, fetal abnormalities 2MSU biofilms research helps set standards for everyday products 2
... White to off-white solid. Increases the expression of ... Soluble in H 2 O. Unstable in ... RTECS EK7713840, CAS 3211-76-5, M.W. 196.1. References: ... L., and Junod, A.F. 1995. Biochem. J. ...
... antifade reagent is used to ... standard fluorescence microscopy. The unique ... a wide variety of fixed ... fluorescein, rhodamine, sulforhodamine 101, coumarin, ...
...
Mouse polyclonal antibody to QDPR - quinoid dihydropteridine reductase...
Biology Products: